Join Benjamin I. Chung, MD and Sandy Srinivas, MD as they present their multidisciplinary expertise on a range of cases pertaining to castrate resistant prostate cancer.

Almost all advanced prostate cancers eventually become resistant to androgen deprivation therapy. Traditionally, docetaxel was the only life-prolonging treatment available for patients with metastatic castration-recurrent prostate cancer (CRPC), albeit with significant side effects. This has changed with a new wave of therapeutic options based on survival benefits including hormone therapy (abiraterone acetate and enzalutamide), immunotherapy (sipuleucel-T), alternate chemotherapy (cabazitaxel), and bone-modulating agents (denosumab and radium-223). The latest agent to receive approval is radium-223, an alpha-emitting radiopharmaceutical and the first bone-targeting agent to prolong overall survival in CRPC patients with bone metastases. Treatment decisions must be tailored individually depending on the presence or absence of symptoms, life expectancy, and performance status of the patient. Sequencing and combination of novel agents is an active area of research, as is the development of additional agents.